• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Your Practice
CNE

No Restrictions: ACOG Supports Over-the-Counter Access to Hormonal Contraception

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Discuss the risk/benefit analysis related to over-the-counter hormonal contraceptive access
2. List the examinations and tests that are required (by the CDC) prior to initiating combined hormonal contraception

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 1/15/2020 through 07/15/2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the test and evaluation. Upon registering and successfully completing the test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Designated for 0.1 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

SUMMARY:

ACOG supports over-the-counter availability of hormonal contraception as a way of reducing inconsistent use or nonuse. Data demonstrates that adherence rates are similar whether hormonal contraception is obtained via a prescriber or over-the-counter. In addition, the ACOG opinion is consistent with AAFP, AMA and APHA in its support of unrestricted access. ACOG does not call for age restrictions except that contraception should not be initiated before menarche.

KEY POINTS:

VTE Risk

  • Progestin-only methods
    • Would incur only “a small increase in absolute numbers of thrombotic events at the population level”
  • Combined hormonal contraceptives (i.e., including estrogen such as ethinyl estradiol)
    • OCPs: 3 to 9 events per 10,000 woman-years of exposure
    • Nonoral (e.g., patch or ring): Evidence inconsistent and if risk present, “likely represents a small number of events on a population level”
    • Note: VTE risks lower than those associated with pregnancy and postpartum which can reach up to 40 to 60 per 10,000 women-years | Other CVD outcomes such as MI or stroke are rare and unclear if there is increased risk | Obesity may raise risk but still below pregnancy risk

Self-Injection

  • Understood that DMPA will require self-administration via subQ
  • Women with certain disorders (e.g., diabetes) are taught how to self-inject and there are studies substantiating successful administration specific to DMPA with appropriate education and training

Self-Screening for Contraindications

General Points

  • Self-screening tools are available and are required to identify women who are not candidates for hormonal contraceptives (see Box 1 in ACOG Opinion with link in ‘Primary Sources – Learn More’ below)
  • Research indicates that women tend to be cautious and self-assessment in most studies did not result incorrect use of OCPs
  • Studies conducted to assess pharmacist screening for behind-the-counter access also demonstrated safety and appropriate use
    • However, ACOG states “Pharmacist-provided contraception may be a necessary intermediate step to increase access to contraception, but over-the-counter access to hormonal contraception should be the ultimate goal.”

DMPA and Progestin-only pills Exam and Lab Requirements (CDC – see ‘Learn More – Primary Sources’)

  • Not required

Combined Hormonal Contraception Exam and Lab Requirements (CDC – see ‘Learn More – Primary Sources’)

  • Blood pressure (Class A)
    • Essential and mandatory in all circumstances for safe and effective use of the contraceptive method
    • In instances in which blood pressure cannot be measured by a provider, blood pressure measured in other settings can be reported by the woman to her provider
  • Weight (BMI)
    • Not needed to determine medical eligibility for any methods of contraception because all methods can be used (U.S. MEC 1) or generally can be used (U.S. MEC 2) among obese women
    • Measuring weight and calculating BMI at baseline might be helpful for monitoring any changes and counseling women who might be concerned about weight change perceived to be associated with their contraceptive method
  • The following all fall under ‘Class C’ which means they do not contribute substantially to safe and effective use of the contraceptive method and therefore would not be required prior to contraceptive use
    • Bimanual examination and cervical inspection
    • Laboratory tests (universal screening in asymptomatic women)
      • Glucose| Lipids | Liver enzymes | Hemoglobin | Thrombogenic mutations | Cervical cytology (Papanicolaou smear) | STD screening with laboratory tests | HIV screening with laboratory tests

Who Should Not Use Combined Hormonal Contraception

VTE WARNING – Category 3 or 4 (risks outweigh benefits or unacceptable risk for)

  • Smoking ≥35 years of age
  • Postpartum <21 days
  • Postpartum 21-42 days with additional risk factors
    • ≥35 years of age | Previous VTE | Thrombophilia | Immobility | Transfusion at delivery | Peripartum Cardiomyopathy | BMI ≥30 | PPH | Postcesarean delivery | preeclampsia | smoking
  • Major surgery with immobilization
  • History of DVT or PE
  • Hereditary thrombophilia including antiphospholipid syndrome
  • Inflammatory Bowel Disease with
    • Active or extensive disease | Surgery | Immobilization | Steroid use | Vitamin deficiencies | Fluid depletion
  • SLE with positive or unknown antiphospholipid antibodies
  • Superficial DVT (acute or history)

Other Issues to Consider Prior To Obtaining Over-The-Counter Combined Hormonal Contraception (Related to Estrogen Component)

  • Aside from ensuring the patient is not a VTE risk (category 3 or 4) and is normotensive, ask about
    • Chance of current pregnancy
    • CVD history (heart attack or stroke)
    • Migraine headaches (with aura)
    • Liver disease or cancer | Gall bladder disease (acute cholecystitis/cholangitis)
    • Breast cancer and other estrogen dependent cancers
    • On medications for hyperlipidemia

Learn More – Primary Sources:

Over-the-Counter Access to Hormonal Contraception

Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate

ACOG Statement on FDA Submission for Over-the-Counter Access to Contraception

Take a post-test and get CME credits

TAKE THE POST TEST

Want to be notified when new guidelines are released? Get ObGFirst!

Learn More »

image_pdfFavoriteLoadingFavorite
< Previous
All Your Practice Posts
Next >

Related ObG Topics:

Emergency Contraception: What, When and How?
Emergency Contraception: What’s your Best Option?
CDC Guidelines on How to Start Combined Hormonal Contraceptives

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site